Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primary prevention.
OBJECTIVE
To assess the prognostic value of cardiac iodine-123 metaiodobenzylguanidine ((123)I-MIBG) scintigraphy to predict ventricular arrhythmias in patients with heart failure (HF) listed for implantable cardioverter-defibrillator (ICD) devices as primary prevention.


METHODS
A prospective cohort study in 27 patients with HF referred for ICD implantation (alone or in combination with cardiac resynchronisation therapy) at a tertiary cardiac centre.


METHODS
Cardiac (123)I-MIBG scintigraphy was performed with calculation of early and late heart-to-mediastinum (H:M) ratios, washout rate, and summed defect score from single photon emission computed tomography (SPECT) acquisition. Resting myocardial perfusion SPECT using (99m)Tc-tetrofosmin was also performed and a summed score calculated. Innervation-perfusion mismatch was evaluated by comparing SPECT scores.


METHODS
Ventricular arrhythmia requiring ICD therapy.


RESULTS
At 16 months median follow-up, 10 (37%) patients experienced a significant arrhythmic event. Compared with patients who suffered no event, these individuals had lower early and late H:M ratio and higher (123)I-MIBG SPECT defect scores: 1.83 ± 0.43 versus 2.34 ± 0.33 (p<0.001); 1.54 ± 0.38 versus 1.96 ± 0.38 (p=0.005); 37.0 ± 9.4 versus 25.5 ± 7.7 (p=0.001). Mismatch scores were also higher: 18.5 ± 8.5 versus 8.4 ± 5.0 (p<0.01). Optimal thresholds for predicting arrhythmia were <1.94 for early H:M ratio (sensitivity 70%, specificity 88%); <1.54 for late H:M ratio (sensitivity 60%, specificity 88%); (123)I-MIBG SPECT defect score ≥31 (sensitivity 78%, specificity 77%).


CONCLUSIONS
In HF patients without prior ventricular arrhythmia, (123)I-MIBG imaging strongly predicts future arrhythmic risk. This may inform the process of case selection for ICD therapy on an individual basis, although no single measurement provides sufficient reassurance to obviate device implantation if otherwise clinically indicated.
Department of Nuclear Medicine, Hareﬁeld Hospital, Royal Brompton & Hareﬁeld NHS Trust, Middlesex, UK. ajmarshall@doctors.org.uk
Andrew
A
Marshall
Andrew
A
Cheetham
Robert S
RS
George
Mark
M
Mason
Andrew D
AD
Kelion
D019797:3-Iodobenzylguanidine; D001145:Arrhythmias, Cardiac / Q000000981:diagnostic imaging / Q000517:prevention & control*; D017147:Defibrillators, Implantable; D005260:Female; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019919:Prosthesis Implantation; D012372:ROC Curve; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon
D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine